All well and good for that form of reasoning Resourced. But the main thing they will be missing out on is the chance to enter the largest market in the world, the US market. They will be years behind once this finally happens, they wont be entering the US for 3 - 5 years. ACL held off on their phase 3 trials for HA-I to wait for Fondaparinux approval, a generic that would be earnings positive in a reletively short timeframe. The market still spanked them knowing they needed funding, in actual fact, and many here know, the shareprice lost over 50% as those with agenda's (larger holders etc) took advantage.
The earnings forecast from TIS clearly shows the first 2 years in Europe will be slow, so the market may take a quick profit before getting stung with a raise. Sure a rise in price leading up to the eventual CE Mark will happen, but once again LT holders could get screwed.
TIS Price at posting:
30.0¢ Sentiment: LT Buy Disclosure: Not Held
